vs
ANGIODYNAMICS INC（ANGO）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是ANGIODYNAMICS INC的1.8倍（$143.1M vs $79.4M）。ANGIODYNAMICS INC净利率更高（-8.0% vs -93.4%，领先85.4%）。GLAUKOS Corp同比增速更快（35.7% vs 9.0%）。ANGIODYNAMICS INC自由现金流更多（$4.2M vs $3.9M）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
ANGO vs GKOS — 直观对比
营收规模更大
GKOS
是对方的1.8倍
$79.4M
营收增速更快
GKOS
高出26.6%
9.0%
净利率更高
ANGO
高出85.4%
-93.4%
自由现金流更多
ANGO
多$310.0K
$3.9M
两年增速更快
GKOS
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $143.1M |
| 净利润 | $-6.3M | $-133.7M |
| 毛利率 | 56.4% | -1.1% |
| 营业利润率 | -7.7% | -97.7% |
| 净利率 | -8.0% | -93.4% |
| 营收同比 | 9.0% | 35.7% |
| 净利润同比 | 40.9% | -298.0% |
| 每股收益（稀释后） | $-0.15 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOGKOS
| Q4 25 | $79.4M | $143.1M | ||
| Q3 25 | $75.7M | $133.5M | ||
| Q2 25 | $80.2M | $124.1M | ||
| Q1 25 | $72.0M | $106.7M | ||
| Q4 24 | $72.8M | $105.5M | ||
| Q3 24 | $67.5M | $96.7M | ||
| Q2 24 | $71.0M | $95.7M | ||
| Q1 24 | $75.2M | $85.6M |
净利润ANGOGKOS
| Q4 25 | $-6.3M | $-133.7M | ||
| Q3 25 | $-10.9M | $-16.2M | ||
| Q2 25 | $-6.0M | $-19.7M | ||
| Q1 25 | $-4.4M | $-18.1M | ||
| Q4 24 | $-10.7M | $-33.6M | ||
| Q3 24 | $-12.8M | $-21.4M | ||
| Q2 24 | $-13.4M | $-50.5M | ||
| Q1 24 | $-187.7M | $-40.8M |
毛利率ANGOGKOS
| Q4 25 | 56.4% | -1.1% | ||
| Q3 25 | 55.3% | 78.4% | ||
| Q2 25 | 52.7% | 78.3% | ||
| Q1 25 | 54.0% | 77.2% | ||
| Q4 24 | 54.8% | 72.9% | ||
| Q3 24 | 54.4% | 76.6% | ||
| Q2 24 | 54.3% | 76.4% | ||
| Q1 24 | 47.7% | 76.3% |
营业利润率ANGOGKOS
| Q4 25 | -7.7% | -97.7% | ||
| Q3 25 | -14.1% | -12.3% | ||
| Q2 25 | -7.2% | -18.3% | ||
| Q1 25 | -13.9% | -19.4% | ||
| Q4 24 | -15.2% | -27.2% | ||
| Q3 24 | -19.4% | -25.5% | ||
| Q2 24 | -20.4% | -31.3% | ||
| Q1 24 | -265.9% | -45.6% |
净利率ANGOGKOS
| Q4 25 | -8.0% | -93.4% | ||
| Q3 25 | -14.4% | -12.2% | ||
| Q2 25 | -7.5% | -15.8% | ||
| Q1 25 | -6.1% | -17.0% | ||
| Q4 24 | -14.7% | -31.8% | ||
| Q3 24 | -19.0% | -22.1% | ||
| Q2 24 | -18.9% | -52.8% | ||
| Q1 24 | -249.7% | -47.7% |
每股收益（稀释后）ANGOGKOS
| Q4 25 | $-0.15 | $-2.34 | ||
| Q3 25 | $-0.26 | $-0.28 | ||
| Q2 25 | $-0.15 | $-0.34 | ||
| Q1 25 | $-0.11 | $-0.32 | ||
| Q4 24 | $-0.26 | $-0.56 | ||
| Q3 24 | $-0.31 | $-0.39 | ||
| Q2 24 | $-0.35 | $-1.00 | ||
| Q1 24 | $-4.67 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $90.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $656.2M |
| 总资产 | $269.7M | $893.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGOGKOS
| Q4 25 | $41.6M | $90.8M | ||
| Q3 25 | $38.8M | $98.2M | ||
| Q2 25 | $55.9M | $100.8M | ||
| Q1 25 | $44.8M | $114.3M | ||
| Q4 24 | $54.1M | $169.6M | ||
| Q3 24 | $55.0M | $100.1M | ||
| Q2 24 | $76.1M | $68.1M | ||
| Q1 24 | $78.5M | $42.5M |
总债务ANGOGKOS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGOGKOS
| Q4 25 | $176.3M | $656.2M | ||
| Q3 25 | $178.9M | $769.5M | ||
| Q2 25 | $183.0M | $765.1M | ||
| Q1 25 | $185.9M | $764.0M | ||
| Q4 24 | $186.8M | $766.9M | ||
| Q3 24 | $196.6M | $668.5M | ||
| Q2 24 | $205.6M | $665.2M | ||
| Q1 24 | $218.7M | $450.7M |
总资产ANGOGKOS
| Q4 25 | $269.7M | $893.5M | ||
| Q3 25 | $265.6M | $999.4M | ||
| Q2 25 | $280.1M | $987.0M | ||
| Q1 25 | $285.4M | $966.2M | ||
| Q4 24 | $291.6M | $974.8M | ||
| Q3 24 | $293.6M | $926.5M | ||
| Q2 24 | $317.7M | $919.7M | ||
| Q1 24 | $324.8M | $933.3M |
负债/权益比ANGOGKOS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $3.9M |
| 自由现金流率自由现金流/营收 | 5.3% | 2.7% |
| 资本支出强度资本支出/营收 | 0.5% | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $-22.5M |
8季度趋势，按日历期对齐
经营现金流ANGOGKOS
| Q4 25 | $4.7M | $6.8M | ||
| Q3 25 | $-15.9M | $-10.1M | ||
| Q2 25 | $18.8M | $7.0M | ||
| Q1 25 | $-13.2M | $-18.5M | ||
| Q4 24 | $2.5M | $507.0K | ||
| Q3 24 | $-18.3M | $-9.6M | ||
| Q2 24 | $5.0M | $-18.4M | ||
| Q1 24 | $-12.5M | $-33.9M |
自由现金流ANGOGKOS
| Q4 25 | $4.2M | $3.9M | ||
| Q3 25 | $-16.6M | $-11.7M | ||
| Q2 25 | $18.0M | $5.8M | ||
| Q1 25 | $-15.0M | $-20.5M | ||
| Q4 24 | $1.7M | $-1.2M | ||
| Q3 24 | $-19.3M | $-11.0M | ||
| Q2 24 | $4.4M | $-20.5M | ||
| Q1 24 | $-13.1M | $-34.8M |
自由现金流率ANGOGKOS
| Q4 25 | 5.3% | 2.7% | ||
| Q3 25 | -22.0% | -8.8% | ||
| Q2 25 | 22.5% | 4.7% | ||
| Q1 25 | -20.8% | -19.2% | ||
| Q4 24 | 2.3% | -1.2% | ||
| Q3 24 | -28.7% | -11.4% | ||
| Q2 24 | 6.2% | -21.4% | ||
| Q1 24 | -17.5% | -40.7% |
资本支出强度ANGOGKOS
| Q4 25 | 0.5% | 2.0% | ||
| Q3 25 | 1.0% | 1.2% | ||
| Q2 25 | 1.0% | 0.9% | ||
| Q1 25 | 2.5% | 1.8% | ||
| Q4 24 | 1.1% | 1.6% | ||
| Q3 24 | 1.6% | 1.5% | ||
| Q2 24 | 0.8% | 2.2% | ||
| Q1 24 | 0.8% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
